Fundraising FoxADRx
Thousand Oaks, US · Delaware corporation · 2 known investors
Find your way into ADRx
Sign up to find every way you can get introduced to ADRx
- Your email: who you already know at ADRx, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ADRx team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Structure-based small-molecule drug design targeting protein aggregation diseases.
Founders & leadership
JT
James TreanorAlso a former CEO
GW
Gary WilcoxNamed on SEC filing
JF
John FrankNamed on SEC filing
MB
Madhavan BalachandranNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$18.1M disclosed across 4 rounds · 2013–2020
▶$6MraisedDec 2020 · 8 investors · BiotechnologyRule 506(b)
▶$6MraisedDec 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Reza HalseDirector
- Gary WilcoxDirector
- Madhavan BalachandranDirector
- Marcin ApostolExecutive Officer
- John FrankDirector
- James TreanorDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Minimum investment
- $60K
- Proceeds to insiders
- $300K
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedOct 2020 · 12 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2020 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary WilcoxDirector
- James TreanorDirector
- John FrankDirector
- Madhavan BalachandranExecutive Officer, Director
- Offering amount
- $5.4M
- Amount sold
- $4M
- Minimum investment
- $16.5K
- Proceeds to insiders
- $250K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedOct 2020 · 19 investors · BiotechnologyRule 506(b)
▶$2.6MraisedOct 2020 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Doug LaneExecutive Officer
- Gary WilcoxDirector
- John FrankDirector
- Madhavan BalachandranExecutive Officer, Director
- James TreanorDirector
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $25K
- Proceeds to insiders
- $360K
- First sale
- Sep 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedOct 2020 · 22 investors · BiotechnologyRule 506(b)
▶$5.6MraisedOct 2020 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary WilcoxDirector
- James TreanorDirector
- John FrankDirector
- Madhavan BalachandranExecutive Officer, Director
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- Minimum investment
- $25K
- Proceeds to insiders
- $412K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ADRx do?
- Structure-based small-molecule drug design targeting protein aggregation diseases.
- Who are ADRx's investors?
- ADRx's investors include MRL Ventures Fund, RA Capital.
- How much funding has ADRx raised?
- ADRx has disclosed $18.1M raised across 4 rounds.
- Where is ADRx headquartered?
- ADRx is headquartered in Thousand Oaks, US.